Malignant pleural mesothelioma: Outcome of limited surgical management

Interactive Cardiovascular and Thoracic Surgery

Volumn 2, Issue 1, 2003, Pages 30-34

  Phillips, Peter G ^a   Asimakopoulos, George ^a   Maiwand, M Omar ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Mesothelioma; Pleural malignancy; Surgery

Indexed keywords

CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; HUMAN; MALIGNANT MESOTHELIOMA; PLEURA; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; SURGICAL MORTALITY; THORACOSCOPY; THORACOTOMY; TREATMENT OUTCOME; VIDEORECORDING;

EID: 0345282959     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9293(02)00093-2     Document Type: Review

References (14)

1. Wagner J.C. The sequelae of exposure to asbestos dust. Ann N Y Acad Sci. 132:1965;691-695.
2. Carbone M., Rizzo P., Pass H. Simian virus 40: the link with human malignant mesothelioma is well established. Anticancer Res. 20:2000;875-877.
3. Butchart E.G., Ashcroft T., Barnsley W.C., Holden M.P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax. 31:1976;15-24.
4. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest. 108:1995;1122-1128.
5. Viallat J.-R., Rey F., Astoul P., Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest. 110:1996;1387-1393.
6. Johansson L., Linden C.J. Aspects of histopathological subtype as a prognostic factor in 85 pleural mesotheliomas. Chest. 109:1996;109-114.
7. Soysal O., Karaoglanoglu N., Demiracan S., Topcu S., Tastepe I., Kaya S., Unlu M., Cetin G. Pleurectomy/decortication for palliation in malignant mesothelioma: results of surgery. Eur J Cardiothorac Surg. 11:1997;210-213.
8. Brancatisano R.R., Joseph M.G., McCaughan B.C. Pleurectomy for mesothelioma. Med J Aust. 154:1991;455-457.
9. Rusch V.W. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 103:1993;382S-384S.
10. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., DeCamp M.M. Jr., Swanson S.J., Bueno R., Lukanich J.M., Baldini E.H., Mentzer S.J. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 117:1999;54-63.
11. Moskal T.L., Dougherty T.J., Urschel J.D., Antkowiak J.G., Regal A.M., Driscoll D.L., Takita H. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg. 66:1998;1128-1133.
12. Rusch V.W., Rosenzweig K., Venkatraman E., Leon L., Raben A., Harrison L., Bains M.S., Downey R.J., Ginsberg R.J. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 122:2001;788-795.
13. Aziz T., Jihaihawi A., Prakash D. The management of malignant pleural mesothelioma: single centre experience in 10 years. Eur J Cardiothorac Surg. 22:2002;298-305.
14. Chahinian A.P., Antman K., Goutsou M., Herndon J.E. 2nd, Aisner J., Ellison R.R., Leone L. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma. J Clin Oncol. 11:1993;1559-1565.